

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2566)

RESTORATION OF PUBLIC FLOAT

References are made to (i) the announcements of the Company dated March 5, 2026, March 25, 2026, April 8, 2026 and May 6, 2026 in relation to the public float; and (ii) the announcement of the Company dated May 14, 2026 in relation to the completion of the H Share Full Circulation (collectively the “**Announcements**”). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcements.

The Board is pleased to announce that the listing (the “**Listing**”) of 136,302,015 H Shares to be converted under the conversion of 136,302,015 Unlisted Shares have been completed as of the date of this announcement. Following the Listing, the issued share capital of the Company solely comprises 245,398,800 H Shares.

To the best of knowledge and belief of the Company, 75,175,601 H Shares, representing approximately 31.13% of the issued share capital of the Company, are held by the public as of the date of this announcement. Accordingly, the public float of the Company has been restored to the Minimum Prescribed Percentage as prescribed by Rule 19A.28B of the Listing Rules.

By order of the Board

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

FU Hang

Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, May 15, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.